Harmony Biosciences Holdings (HRMY) Income from Continuing Operations (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Income from Continuing Operations of 32488000.0 for Q1 2026, down 50.22% sequentially from 65262000.0 in Q4 2025, and down 28.69% YoY from 45560000.0 in Q1 2025.
Harmony Biosciences Holdings (HRMY) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Income from Continuing Operations for 8 years, with the latest figure at 32488000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 28.69% year-over-year to 32488000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 188391000.0 (up 23.36% YoY) and the FY2025 annual result came in at 201463000.0, up 38.47% from the prior year.
- Income from Continuing Operations fell to 32488000.0 in Q1 2026 per HRMY's latest filing, from 65262000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 87943000.0 in Q3 2022 and troughed at 11591000.0 in Q2 2024.
- A 5-year average of 40574411.76 and a median of 38461000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 1014.17% in 2022, then tumbled 66.21% in 2024.
- Over 5 years, Income from Continuing Operations stood at 48509000.0 in 2022, then sank by 45.15% to 26607000.0 in 2023, then surged by 85.95% to 49475000.0 in 2024, then soared by 31.91% to 65262000.0 in 2025, then tumbled by 50.22% to 32488000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 32488000.0, 65262000.0, and 50865000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 73.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.68 Mn |
| Mar 31, 2026 | 32.49 Mn |
| Dec 31, 2025 | 65.26 Mn |
| Sep 30, 2025 | 50.87 Mn |
| Jun 30, 2025 | 39.78 Mn |
| Mar 31, 2025 | 45.56 Mn |
| Dec 31, 2024 | 49.48 Mn |
| Sep 30, 2024 | 46.09 Mn |
| Jun 30, 2024 | 11.59 Mn |
| Mar 31, 2024 | 38.33 Mn |
| Dec 31, 2023 | 26.61 Mn |
| Sep 30, 2023 | 38.46 Mn |
| Jun 30, 2023 | 34.30 Mn |
| Mar 31, 2023 | 29.49 Mn |
| Dec 31, 2022 | 48.51 Mn |
| Sep 30, 2022 | 87.94 Mn |
| Jun 30, 2022 | 23.53 Mn |
| Mar 31, 2022 | 21.49 Mn |
| Dec 31, 2021 | 22.71 Mn |
| Sep 30, 2021 | -9.62 Mn |